Erola T, Heikkinen E R, Haapaniemi T, Tuominen J, Juolasmaa A, Myllylä V V
Department of Neurosurgery, Oulu University Hospital, Oulu, Finland.
Acta Neurochir (Wien). 2006 Apr;148(4):389-94. doi: 10.1007/s00701-005-0662-8. Epub 2005 Nov 14.
Deep brain stimulation (DBS) has, for the most part, replaced irreversible stereotactic coagulations in the surgical treatment of advanced Parkinson's disease. This study was undertaken to evaluate the benefits of bilateral STN stimulation related to its potential risks and side effects.
Twenty-nine consecutive Parkinsonian patients treated with STN-DBS were prospectively followed-up. Effects on Parkinsonian symptoms were evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS). The evaluation was performed preoperatively and included postoperative follow-up evaluations at one and twelve months. All evaluations were made during the patient's best on-medication phase and postoperative follow-ups were conducted under both stimulator-on and stimulator-off conditions by a blinded neurologist. A neuropsychologist also evaluated the patients at every visit.
Two patients were excluded from the analysis because of severe surgical complications and three for an infection demanding the removal of the stimulator material. Other complications and side effects were clearly milder and temporary. At twelve months after surgery dyskinesia scores in the UPDRS were 53% lower than preoperative values. The results of the UPDRS motor scores improved 31.4% and activities of daily living (ADL) scores increased 19% compared with the preoperative situation. Also, the daily levodopa dose was 22% lower. Neuropsychological changes were minor, except for some deterioration in verbal fluency.
The majority of Parkinsonian patients experienced significant and long lasting relief from their motor symptoms and an improvement in ADL functions due to DBS-STN therapy when evaluated at the best on-medication phase.
在晚期帕金森病的外科治疗中,深部脑刺激(DBS)在很大程度上已取代了不可逆的立体定向凝固术。本研究旨在评估双侧丘脑底核(STN)刺激的益处及其潜在风险和副作用。
对连续29例接受STN-DBS治疗的帕金森病患者进行前瞻性随访。使用统一帕金森病评定量表(UPDRS)评估对帕金森病症状的影响。评估在术前进行,并包括术后1个月和12个月的随访评估。所有评估均在患者最佳药物治疗阶段进行,术后随访由一名盲法神经科医生在刺激器开启和关闭两种情况下进行。一名神经心理学家在每次就诊时也对患者进行评估。
两名患者因严重手术并发症被排除在分析之外,三名患者因感染需要取出刺激器材料而被排除。其他并发症和副作用明显较轻且为暂时性。术后12个月,UPDRS中的异动症评分比术前值低53%。与术前情况相比,UPDRS运动评分结果改善了31.4%,日常生活活动(ADL)评分提高了19%。此外,左旋多巴每日剂量降低了22%。除言语流畅性略有下降外,神经心理学变化较小。
在最佳药物治疗阶段进行评估时,大多数帕金森病患者因DBS-STN治疗而在运动症状方面获得了显著且持久的缓解,ADL功能也得到了改善。